Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04712877 · ClinicalTrials.gov registry record

Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers

A clinical trial of NSCLC, sponsored by Lung Cancer Mutation Consortium.

Recruiting
Registry status
1,000
Enrollment target
20
Study locations

NCT04712877: Recruiting study of NSCLC, sponsored by Lung Cancer Mutation Consortium.

NCT04712877 is a study of NSCLC that is actively recruiting participants, run by Lung Cancer Mutation Consortium. The registered enrollment target is 1,000 participants, above the 210-participant average among 71 other NSCLC trials with a reported enrollment target (376% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04712877, a study of NSCLC, is actively recruiting participants, sponsored by Lung Cancer Mutation Consortium.

RECRUITING
Registry status
1,000 participants
Enrollment target
20
Study locations

Study Summary

This collaborative screening protocol, developed by the Lung Cancer Mutation Consortium (LCMC) and supported by the Thoracic Surgery Oncology Group (TSOG), is designed to determine the feasibility of comprehensive molecular profiling to detect actionable oncogenic drivers in patients with suspected early stage lung cancers scheduled to undergo biopsies to establish the diagnosis of lung cancer. The primary purpose of this testing is to determine the presence of 12 oncogenic drivers (mutations in EGFR, BRAFV600E , MET exon 14, KRAS G12C and HER2, rearrangements in ALK, RET, NTRK, EGFR exon 20 insertion and ROS1, and amplification of MET and HER2) that can serve as targets making patients eligible for upcoming targeted neoadjuvant therapy trials. The ultimate goal is to use this information from the screening process to select the optimal neoadjuvant therapy and wherever possible enroll patients onto separate neoadjuvant therapy trials with genomically matched treatments or other appropriate trials if no actionable driver mutation is detected. Thoracic Surgery Oncology Group (TSOG) is a network of surgeons within North American Thoracic Surgery Academic Centers aligned with the goal of enhancing patient care through administration of multi-site trials focused on recent advances in lung cancer. TSOG has aligned with the LCMC4 sites to enroll the LCRF-LEADER screening trial. TSOG's involvement will be essential in trial enrollment and ultimate interpretation of the multimodal clinical and translational data collected as part of this study. We estimate we will detect an actionable oncogenic driver in 33% of cases. The remaining 66% of patients will represent a cohort identified by their care teams as candidates for other potential neoadjuvant therapies which may include checkpoint inhibitors such as atezolizumab, durvalumab, nivolumab, and pembrolizumab or other novel agents. The targeted therapy treatment trials will be conducted independently of the LCRF-LEADER scre

Conditions Studied

NSCLC

Interventions

  • DIAGNOSTIC_TEST ctDNA, tumor NGS

Study Locations (20)

California

  • University of California, Davis - Davis
  • USC Norris Comprehensive Cancer Center - Los Angeles
  • UCLA - Los Angeles
  • St. Joseph's Hospital Orange - Orange

Massachusetts

  • Massachusetts General Hospital - Boston
  • Brigham and Women's Hospital - Boston
  • Boston Medical Center - Boston
  • Dana-Farber Cancer Institute - Boston

Missouri

  • University of Missouri - Columbia
  • Washington University - St Louis

New York

  • NYU - New York
  • Columbia University - New York

Florida

  • Moffitt Cancer Center - Tampa

Illinois

  • Northwestern University - Chicago

Michigan

  • University of Michigan - Ann Arbor

New Hampshire

  • Dartmouth-Hitchcock - Lebanon

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2022-06-15
Est. Completion 2026-06-15
Lung Cancer Mutation Consortium

1 total trials

What NCT04712877 shows while recruiting

NCT04712877 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 210-participant average among 71 other NSCLC trials with a reported enrollment target (376% higher).

The record links to 1 condition, with NSCLC appearing as the primary indexed condition, and to 1 intervention - of which ctDNA, tumor NGS is the first listed.

NCT04712877 names 20 study sites across 12 states, led by California, Massachusetts, Missouri.

Frequently Asked Questions

What is clinical trial NCT04712877 about?

NCT04712877 is a clinical study titled "Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers". This collaborative screening protocol, developed by the Lung Cancer Mutation Consortium (LCMC) and supported by the Thoracic Surgery Oncology Group (TSOG), is designed to determine the feasibility of comprehensive molecular profiling to detect actionable oncogenic drivers in patients with suspected ...

What is the current status of trial NCT04712877?

This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2022-06-15. Estimated completion is 2026-06-15.

What conditions does trial NCT04712877 study?

This clinical trial studies the following conditions: NSCLC.

What interventions are being tested in trial NCT04712877?

The interventions under investigation include: ctDNA, tumor NGS (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT04712877?

This trial is sponsored by Lung Cancer Mutation Consortium, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04712877 being conducted?

This trial has 20 study locations across California, Florida, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for NSCLC

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04712877's enrollment target sits among peer trials

1,000 2nd of 71 the highest of 71 other NSCLC trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NSCLC trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00018044 · 1,000 participants

    Study of Mycobacterial Infections

  • NCT01036581 · 1,000 participants · NA

    Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging

  • NCT01192048 · 1,000 participants

    Genetics of Congenital Heart Disease

  • NCT01553214 · 1,000 participants · Phase 4

    Improving White Blood Cell Collection From Healthy Donors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT04712877

Source: ClinicalTrials.gov NCT04712877, the US trial registry maintained by the National Library of Medicine. NCT04712877 (large enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.